Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18800329 | BEAUVERIA BASSIANA STRAIN WITH HIGH ULTRAVIOLET RADIATION RESISTANCE AS WELL AS DIRECTIONAL MUTAGENESIS METHOD THEREFOR AND USE THEREOF | August 2024 | May 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18498577 | ADENO-ASSOCIATED VIRUS (AAV) PRODUCER CELL LINES | October 2023 | May 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18082506 | APPLICATION OF VEGFR GENE EXPRESSION INHIBITOR IN PREPARING PREPARATION OR AS PREPARATION FOR TREATING PSORIASIS | December 2022 | June 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17935492 | PROMOTING NUTRIENT ABSORPTION THROUGH THE COLON | September 2022 | May 2025 | Allow | 31 | 2 | 0 | No | No |
| 17711975 | COMBINATIONS OF SIRNAS WITH SIRNAS AGAINST SULF2 OR GPC3 FOR USE IN TREATING CANCER | April 2022 | March 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17435161 | KIT, DEVICE, AND METHOD FOR DETECTING UTERINE LEIOMYOSARCOMA | August 2021 | March 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17311502 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING NASH, NAFLD, DIABETES, ATHEROSCLEROSIS, AND/OR OBESITY | June 2021 | May 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17298896 | PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS | June 2021 | April 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17331398 | Gold Optimized CAR T-cells | May 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17290298 | MicroRNA Compounds and Methods for Modulating MIR-10B Activity | April 2021 | February 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17283845 | MYOCARDIAL ENHANCER RNA AND METHODS OF USE | April 2021 | January 2025 | Allow | 46 | 1 | 1 | No | No |
| 17276320 | INCREASING GENE EXPRESSION | March 2021 | June 2024 | Allow | 39 | 2 | 0 | No | No |
| 17276201 | METHOD FOR EXTENDING TELOMERE OF CELL | March 2021 | January 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17265749 | AAV VARIANTS WITH ENHANCED TROPISM | February 2021 | April 2025 | Allow | 51 | 1 | 1 | No | No |
| 17265489 | VARIANT RNAi AGAINST ALPHA-SYNUCLEIN | February 2021 | March 2025 | Allow | 49 | 2 | 1 | No | No |
| 17147797 | OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION | January 2021 | June 2025 | Allow | 53 | 2 | 1 | No | No |
| 17252584 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND DISORDERS ASSOCIATED WITH THE SPINAL CORD | December 2020 | January 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17055972 | METHODS AND COMPOSITIONS FOR USING METAL ELEMENTS IN AAV GENE THERAPY | November 2020 | April 2025 | Abandon | 52 | 3 | 0 | No | No |
| 16980369 | Assessing Transplant Rejection Status by Analysis of T-Cell Receptor Subunit Repertoire Diversity | September 2020 | March 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 16347134 | METHOD OF DETECTING TUMOUR RECURRENCE | May 2019 | January 2025 | Allow | 60 | 5 | 2 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MCKILLOP, JOHN CHARLES works in Art Unit 1637 and has examined 19 patent applications in our dataset. With an allowance rate of 52.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner MCKILLOP, JOHN CHARLES's allowance rate of 52.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCKILLOP, JOHN CHARLES receive 1.74 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MCKILLOP, JOHN CHARLES is 46 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +56.2% benefit to allowance rate for applications examined by MCKILLOP, JOHN CHARLES. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.